Abstract 1514P
Background
Pancreatic cancer is characterized by a dense fibrous stroma and poor blood supply, which hampers effective drug delivery and treatment outcomes. Hence, there is an immediate necessity of novel therapeutic strategies to improve drug penetration in the tumor microenvironment of pancreas. The ‘IMD10’ System has been developed to optimize focused ultrasound for the purpose of drug delivery in solid tumors. This clinical trial was designed to evaluate the efficacy and safety of concurrent treatment with FOLFIRINOX chemotherapy with the 'IMD10' non-tissue destructive bedside-applicable focused ultrasound device, in patients with locally advanced (LAPC) or borderline resectable pancreatic cancer (BRPC).
Methods
30 patients of LAPC or BRPC participated. The intervention group (N=15) received a total of four combined treatments at two-week intervals for 2 months, followed by standard care. The control group (N=15) received treatment according to the standard FOLFIRINOX regimen. Safety and efficacy were evaluated up to 6 months after the initiation of the first treatment. Primary efficacy assessment variable was the target lesion size change ratio (%), while secondary efficacy evaluations comprised tumor response and objective response rate (ORR). Adverse events were also recorded.
Results
Immediately after completion of the intervention, the target lesion size change ratio was -24.89% in the intervention group and -14.05% in the control group. This trend persisted until 4 months after the intervention. The ORR was 64.3% in the intervention group and 38.5% in the control group, with no significant differences observed in adverse events between the groups.
Conclusions
The target lesion size change ratio was 1.8 times greater in the intervention group, and the ORR was 1.7 times greater compared to the control group. Considering bedside applicable compact size of IMD 10 designed for drug delivery, we believe there are sufficient clinical potentials. However, larger confirmatory clinical trials are needed to further substantiate these findings.
Clinical trial identification
none
Editorial acknowledgement
During the preparation of this work the author(s) used Chat GPT in order to check up grammatical and usage errors. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.
Legal entity responsible for the study
J. Y. Lee.
Funding
Korea Medical Device Development Fund grant funded by the Korea Government (the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health & Welfare, the Ministry of Food and Drug Safety) (Project Number: RS-2020-KD000000).
Disclosure
J.Y. Lee: Financial Interests, Personal, Stocks/Shares: IMGT. All other authors have declared no conflicts of interest.
Resources from the same session
1525P - Nab-paclitaxel/gemcitabine with or without epigenetic targeting followed by consolidating immune targeting with durvalumab and lenalidomide in patients with advanced pancreatic ductal adenocarcinoma: Results from the SEPION/AIO-PAK-0118 phase I/II study
Presenter: Jens Siveke
Session: Poster session 18
1527P - GnP vs mFOLFIRINOX or S-IROX in metastatic pancreatic cancer: 1-year follow-up updated data from the GENERATE (JCOG1611)
Presenter: Satoshi Kobayashi
Session: Poster session 18
1528P - TCOG T5221 trial: A phase II randomized study of gemcitabine and nab-paclitaxel in combination with S- 1/LV (GASL) or oxaliplatin (GAP) as first-line treatment for metastatic pancreatic cancer
Presenter: Yung-yeh Su
Session: Poster session 18
1531TiP - TWINPEAK phase I/II study, PT886 a bispecific antibody targeting claudin 18.2 and CD47 in combination with chemotherapy and/or pembrolizumab in gastric/GEJ-carcinomas or PDAC
Presenter: Michael Overman
Session: Poster session 18
1532TiP - Zolbetuximab with gemcitabine + nab-paclitaxel (GN) in first-line treatment of Claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase II, open-label, randomized study
Presenter: Wungki Park
Session: Poster session 18
1533TiP - A multicenter, open-label phase II study to evaluate the efficacy and safety of pimicotinib (CSF-1R inhibitor) in combination with chemotherapy with or without toripalimab in patients (pts) with advanced pancreatic ductal adenocarcinoma (aPDAC)
Presenter: Xiaofei Zhang
Session: Poster session 18
1534TiP - Valproic acid combinEd with Simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic Pancreatic Adenocarcinoma patients-VESPA trial
Presenter: Alfredo Budillon
Session: Poster session 18